FDA

Digital

Health Innovators – Amy Abernethy and Jennifer Goldsack Part...

Verily’s Amy Abernethy and DiMe’s Jennifer Goldsack return for a second conversation on data and healthcare, this one focusing on specific use cases and examples.

Patients

Colorful painted group of people figures

To build diversity into clinical trials, collaborate at the ...

Diversity in clinical trials is a “scientific imperative”, but how can industry bridge the gap between “why” and “how”?

News

bluebird unveils $2.8m price for gene therapy Zynteglo on FD...

bluebird bio's Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require re

R&D

How Pharmacogenomics may finally realise its promise

More than 60 percent of a

News

AZ gets FDA nod for Enhertu in first HER2-low cancer

The FDA has approved AstraZeneca and Daiichi Sankyo's Enhertu as the first targeted therapy for HER2-low breast cancer, a new category of the disease that was once lumped under the HER2-neg

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

FDA verdict on Enhertu in HER2-low breast cancer due before ...

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license application for Enhertu in HER2-low breast cancer – an indication which could drive the dr

Health Innovators – Amy Abernethy and Jennifer Goldsack Part...

To build diversity into clinical trials, collaborate at the ...

bluebird unveils $2.8m price for gene therapy Zynteglo on FD...

How Pharmacogenomics may finally realise its promise

AZ gets FDA nod for Enhertu in first HER2-low cancer

FDA verdict on Enhertu in HER2-low breast cancer due before ...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

FDA

Editor's Picks